Allarity Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $3.40 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Allarity Therapeutics Inc had its IPO on 2021-12-21 under the ticker symbol ALLR.
The company operates in the Healthcare sector and Biotechnology industry. Allarity Therapeutics Inc has a staff strength of 13 employees.
Shares of Allarity Therapeutics Inc opened at $0.09 at the start of the last trading session i.e. 2023-03-25.
The stocks traded within a range of $0.07 - $0.1, and closed at $0.08.
This is a -31.86% slip from the previous day's closing price.
A total volume of 19,782,200 shares were traded at the close of the day’s session.
In the last one week, shares of Allarity Therapeutics Inc have slipped by -33.62%.
Allarity Therapeutics Inc's Key Ratios
Allarity Therapeutics Inc has a market cap of $3.40 million, indicating a price to book ratio of 2.659 and a price to sales ratio of 0.
In the last 12-months Allarity Therapeutics Inc’s revenue was $-7127000 with a gross profit of $-36348000 and an EBITDA of $-29374000. The EBITDA ratio measures Allarity Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Allarity Therapeutics Inc’s operating margin was 0% while its return on assets stood at -88.33% with a return of equity of -259.33%.
In Q3, Allarity Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Allarity Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-3.61 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Allarity Therapeutics Inc’s profitability.
Allarity Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.0989. Its price to sales ratio in the trailing 12-months stood at 0.
Allarity Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $23.19 million
- Total Liabilities
- $11.19 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Allarity Therapeutics Inc ended 2023 with $23.19 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.19 million while shareholder equity stood at $8.20 million.
Allarity Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $11.19 million in other current liabilities, 929000.00 in common stock, $-74229000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.64 million and cash and short-term investments were $7.64 million. The company’s total short-term debt was $54,000 while long-term debt stood at $1.06 million.
Allarity Therapeutics Inc’s total current assets stands at $10.08 million while long-term investments were $0.00 and short-term investments were $0. Its net receivables were $1.43 million compared to accounts payable of $5.56 million and inventory worth $0.
In 2023, Allarity Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Allarity Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Allarity Therapeutics Inc stock is currently trading at $0.08 per share. It touched a 52-week high of $3.38 and a 52-week low of $3.38. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $0.19 and 200-day moving average was $0.76 The short ratio stood at 0.14 indicating a short percent outstanding of 0%.
Around 1071.1% of the company’s stock are held by insiders while 62% are held by institutions.
Frequently Asked Questions About Allarity Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.